Chardan Capital analyst Keay Nakae reiterated a Buy rating on Achilles Therapeutics (ACHL – Research Report) today. The company's shares closed last Friday at $2.22, close to its 52-week low of $2.11. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 8.1% and a 38.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals. Achilles Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.50.
https://www.tipranks.com/news/blurbs/chardan-capital-thinks-achilles-therapeutics-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral